FDA – Page 59 – Pharma.Tips

Partner IP obligations missed during lifecycle management – risk mitigation and governance actions

Addressing Missed Partner IP Obligations During Lifecycle Management In the pharmaceutical industry, lifecycle management is crucial for maintaining compliance with partner intellectual property (IP) obligations. The risks associated with missed…

Chemical exposure incident during emergency response – compliance remediation strategy

Remediation Strategies for Compliance Following a Chemical Exposure Incident During Emergency Response In the highly regulated atmosphere of pharmaceutical manufacturing, a chemical exposure incident during an emergency response can pose…

IP risks during tech transfer during due diligence – documentation expectations for audits

Understanding IP Risks During Tech Transfer: Documentation Expectations for Effective Audits In the pharmaceutical industry, tech transfers are critical processes that facilitate the movement of products from development to manufacturing.…

Contractor safety breach during routine operations – how to withstand inspections

Addressing Contractor Safety Breaches During Routine Operations: Ensuring Inspection Readiness In the pharmaceutical manufacturing arena, maintaining the integrity of operations is paramount, especially when contractor safety breaches occur during routine…

Partner IP obligations missed during development – business and regulatory impact analysis

Assessing Missed Partner IP Obligations During Development: An Investigation Approach During pharmaceutical development, missed obligations related to partner intellectual property (IP) can manifest as deviations, operational failures, or compliance issues…

Waste handling non-compliance during incident investigation – CAPA escalation pathway

Addressing Waste Handling Non-Compliance in Incident Investigations: A CAPA Escalation Pathway In the pharmaceutical industry, adherence to waste handling regulations is critical not only for compliance but also for maintaining…

Patent strategy misalignment during lifecycle management – business and regulatory impact analysis

“`html Understanding and Investigating Patent Strategy Misalignment During Lifecycle Management In the complex landscape of pharmaceutical operations, aligning patent strategy with lifecycle management is critical to ensuring compliance and maintaining…

Contractor safety breach during incident investigation – CAPA escalation pathway

Investigating Contractor Safety Breaches During an Incident: A CAPA Escalation Pathway In the pharmaceutical industry, safety breaches involving contractors can lead to significant compliance issues, hamper operational efficiency, and potentially…

IP risks during tech transfer during partnership discussions – risk mitigation and governance actions

Understanding and Mitigating IP Risks during Partnership Discussions in Tech Transfer In the increasingly complex pharmaceutical landscape, effectively managing intellectual property (IP) risks during tech transfer is crucial when engaging…

Safety training gap during inspection – regulatory enforcement risk

Addressing Safety Training Gaps During Inspections: A Pragmatic Approach Pharmaceutical manufacturers are increasingly cognizant of the critical importance of robust safety training, particularly during audits and inspections. A gap in…

Patent strategy misalignment during due diligence – documentation expectations for audits

Addressing Patent Strategy Misalignment During Due Diligence: Ensuring Compliance and Readiness for Audits In the highly regulated pharmaceutical industry, misalignment in patent strategy during due diligence can lead to significant…

Contractor safety breach during inspection – compliance remediation strategy

Addressing Contractor Safety Breaches During Pharmaceutical Inspections In the high-stakes environment of pharmaceutical manufacturing, contractor safety breaches during inspections can lead to significant regulatory scrutiny and compliance risks. With recent…